Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
| Autor: | Stephen B. Hanauer, Omoniyi J. Adedokun, Christopher Gasink, Subrata Ghosh, Jewel Johanns, Zhenhua Xu, Philippe Szapary, Hugh M. Davis, William J. Sandborn, Long Long Gao, Douglas Jacobstein, Brian G. Feagan |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Severity of Illness Index Gastroenterology Maintenance Chemotherapy 03 medical and health sciences 0302 clinical medicine Crohn Disease Pharmacokinetics Internal medicine Ustekinumab medicine Clinical endpoint Humans Adverse effect Dose-Response Relationship Drug Hepatology business.industry Maintenance dose Area under the curve Antibodies Monoclonal Induction Chemotherapy Crohn's Disease Activity Index C-Reactive Protein Treatment Outcome 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology Methotrexate business Biomarkers medicine.drug |
| Zdroj: | Gastroenterology. 154:1660-1671 |
| ISSN: | 0016-5085 |
| DOI: | 10.1053/j.gastro.2018.01.043 |
| Popis: | Background & Aims Ustekinumab is a monoclonal antibody that binds with high affinity to the p40 subunit of human interleukin 12 (IL12 and IL23) that has been approved for treatment of patients with moderate to severe Crohn's disease (CD). However, there are few data on its pharmacokinetic properties or the relationship between drug exposure levels and patient response. We collected data from 2 Phase 3 induction studies and 1 maintenance study to determine ustekinumab's pharmacokinetic features, relationship between exposure and response, and optimal serum concentrations for efficacy. Methods We collected data on serum concentrations of ustekinumab and efficacy from induction studies of patients with moderate to severe CD given ustekinumab for 8 weeks following a single intravenous dose (either 130 mg or approximately 6 mg/kg). We collected the same data from a maintenance study of patients with a response to ustekinumab in the induction study who then received subcutaneous injections (90 mg) every 8 or 12 weeks for 44 weeks. At week 44 of the maintenance study (52 weeks after treatment began), patients were evaluated for the primary endpoint of clinical remission (defined as a CD activity index score below 150 points), endoscopic markers of efficacy, and serum level of C-reactive protein. Ustekinumab concentration data were categorized into quartiles and relationships between exposure and response were assessed. Optimal concentration cutoff values were evaluated using receiver operating characteristic curve analysis. Results Serum concentrations of ustekinumab over time were proportional to dose and did not differ significantly between the induction studies. In the maintenance study, ustekinumab concentration reached the steady state by the second maintenance dose; the median trough concentration was approximately threefold higher in patients given ustekinumab at 8-week intervals compared with 12-week intervals. Ustekinumab serum concentrations associated with rates of clinical remission and endoscopic efficacy endpoints, correlated inversely with level of C-reactive protein, and did not associate with use of immunomodulators. Trough concentrations of ustekinumab of 0.8 (or even up to 1.4 μg/mL) or greater were associated with maintenance of clinical remission in a higher proportion of patients than patients with lower trough concentrations. Conclusions In an analysis of data from Phase 3 studies of patients with moderate to severe CD, we found serum concentrations of ustekinumab to be proportional to dose and associate with treatment efficacy. Concentrations of ustekinumab did not seem to be affected by cotreatment with immunomodulators. Clinicaltrials.gov no. NCT01369329 (UNITI 1), NCT01369342 (UNITI 2), and NCT01369355 (IM-UNITI). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|